Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study
Open Access
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (2) , 245-253
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant ChemotherapyInternational Journal of Gynecological Cancer, 2015
- Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination2015
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal CarcinomasClinical Cancer Research, 2014
- PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cellsCarcinogenesis, 2012
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)International Journal of Gynecological Cancer, 2011
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinCancer Research, 2010
- ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsClinical Cancer Research, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- The PARP superfamilyBioEssays, 2004
- Structural Model Evaluation and Modification: An Interval Estimation ApproachMultivariate Behavioral Research, 1990